<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00994968</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000650694</org_study_id>
    <secondary_id>YONSEI-YCC-BR09-01</secondary_id>
    <nct_id>NCT00994968</nct_id>
  </id_info>
  <brief_title>Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer</brief_title>
  <official_title>Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Docetaxel and S-1 in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide,&#xD;
      docetaxel, and S-1, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells or by stopping them from dividing. Giving more than one drug (combination&#xD;
      chemotherapy) before surgery may make the tumor smaller and reduce the amount of normal&#xD;
      tissue that needs to be removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying giving doxorubicin hydrochloride together with&#xD;
      cyclophosphamide, docetaxel, and S-1 before surgery in treating women with stage II or stage&#xD;
      III breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the rate of pathologic complete response in women with previously untreated&#xD;
           stage II or III breast cancer treated with neoadjuvant doxorubicin hydrochloride and&#xD;
           cyclophosphamide followed by docetaxel and S1.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety and tolerability of this regimen in these patients.&#xD;
&#xD;
        -  Determine the rate of overall radiologic response in these patients.&#xD;
&#xD;
        -  Determine the rate of breast-conserving procedures in these patients.&#xD;
&#xD;
        -  Determine the disease-free survival of these patients.&#xD;
&#xD;
        -  Investigate the relevant pharmacogenomics and biomarker(s) which will be useful to&#xD;
           predict any responses to the anticancer treatments.&#xD;
&#xD;
      OUTLINE: Patients receive neoadjuvant doxorubicin hydrochloride IV and cyclophosphamide IV on&#xD;
      day 1. Treatment repeats every 3 weeks for up to 4 courses. Patients then receive docetaxel&#xD;
      IV over 1 hour on day 1 and oral S-1 on days 1-14. Treatment repeats every 3 weeks for 4&#xD;
      courses. Two to four weeks later, patients undergo surgery to remove the tumor (either&#xD;
      breast-conserving procedures or mastectomy). Patients may then undergo radiotherapy and&#xD;
      receive endocrine therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of pathologic complete response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of overall radiologic response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of breast-conserving procedure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relevant pharmacogenomics and biomarker(s) which may be useful to predict any responses to the anticancer treatments</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">49</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tegafur-gimeracil-oteracil potassium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed invasive primary breast cancer&#xD;
&#xD;
               -  Clinical (radiologic) stage II or III disease&#xD;
&#xD;
               -  No T4d disease&#xD;
&#xD;
               -  No inflammatory breast cancer&#xD;
&#xD;
          -  ErbB2-negative disease OR patient cannot receive trastuzumab treatment&#xD;
&#xD;
               -  ErbB2-positive disease defined as either immunohistochemistry 3+, or FISH- or&#xD;
                  CISH-positive; immunohistochemistry 2+ is to be determined according to FISH or&#xD;
                  CISH results&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Mobile&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Normal cardiac function (LVEF &gt; 50%)&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/μL&#xD;
&#xD;
          -  Platelet count ≥ 10 x 10^4/μL&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
          -  AST/ALT ≤ 2.5 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to swallow tablet whole with water&#xD;
&#xD;
          -  No prior motor or sensory neurotoxicity CTCAE ≥ grade 2&#xD;
&#xD;
          -  No other serious disease or medical condition&#xD;
&#xD;
          -  No uncontrolled or serious cardiovascular disease, including any of the following:&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  New York Heart Association class III or IV heart failure&#xD;
&#xD;
               -  Uncontrolled angina pectoris&#xD;
&#xD;
               -  Clinically significant pericardial disease&#xD;
&#xD;
               -  Cardiac amyloidosis&#xD;
&#xD;
          -  No history of symptomatic or therapy-requiring cardiac arrhythmia CTCAE grade 3 (e.g.,&#xD;
             multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular&#xD;
             tachycardia, uncontrolled atrial fibrillation)&#xD;
&#xD;
          -  No asymptomatic sustained ventricular tachycardia&#xD;
&#xD;
          -  History of atrial fibrillation or cardiac arrhythmia controlled by medication allowed&#xD;
&#xD;
          -  No uncontrolled infection, unstable peptic ulcer, uncontrolled diabetes, or any other&#xD;
             contraindication to corticosteroid administration&#xD;
&#xD;
          -  No history of infection or any other serious medical event which may cause any&#xD;
             functional injury in the affected patient and consequently, interfere with continuing&#xD;
             the study treatment&#xD;
&#xD;
          -  No history of hypersensitivity to taxanes, fluorouracil, or S-1&#xD;
&#xD;
          -  No significant gastrointestinal malfunction that will affect S-1 absorption&#xD;
&#xD;
          -  No history of other cancer within the past 5 years except properly treated carcinoma&#xD;
             in situ of the uterine cervix or basal cell or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  No severe psychological or neurological disorder or dementia that would preclude&#xD;
             understanding of the informed consent&#xD;
&#xD;
          -  No psychological, social, family, or geographical condition, or difficult circumstance&#xD;
             that would preclude follow-up or compliance with the protocol&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior systemic treatment for this cancer (e.g., radiotherapy, chemotherapy, hormone&#xD;
             therapy, or biological therapy)&#xD;
&#xD;
          -  No prior preoperative topical treatments (e.g., incomplete surgery or radiotherapy)&#xD;
             for this cancer&#xD;
&#xD;
          -  No concurrent drug(s) that may potentially cause changes in the pharmacological&#xD;
             activity of S-1 formulation, including any of the following:&#xD;
&#xD;
               -  Allopurinol&#xD;
&#xD;
               -  Phenytoin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joo Hyuk Sohn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei Cancer Center at Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joo Hyuk Sohn, MD, PhD</last_name>
      <phone>82-2-2228-8130</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>October 13, 2009</study_first_submitted>
  <study_first_submitted_qc>October 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>October 28, 2010</last_update_submitted>
  <last_update_submitted_qc>October 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2010</last_update_posted>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage III breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

